Session 53 - 12th CROI

Home

Session 53 Poster Abstracts
Host-Cell Restriction Factors: Vif, Apobec, Trim5, and Cyclophilin
Wednesday, 1:30 - 3:30 pm
Hall D

231	Modulation of TRIM5ala-mediated Restriction Activity in Primate Cell Lines Sarah Sebastian*, L Berthoux, and J Luban Columbia Univ, New York, NY, USA
232	Target Cell Cyclophilin A Modulates HIV-1 Infectivity Elena Sokolskaja*, D Sayah, and J Luban Columbia Univ, New York, NY, USA
233	A Naturally Occurring Capsid Motif Governs HIV-1 Defense against Innate Primate Restrictions U Chatterji¹, M Bobardt¹, R Ptak², L Pallansch², P Ward², M Jones², C Stoddart³, A Saphire¹, P Scalfaro⁴, J M Dumont⁴, K Besseghir⁴, B Rosenwirth⁵, and Philippe Gallay*¹ ¹The Scripps Res Inst, La Jolla, CA, USA; ²Southern Res Inst, Frederick, MD, USA; ³Gladstone Inst of Virology and Immunology, Univ of California, San Francisco, USA; ⁴Debiopharm, Lausanne, Switzerland; and ⁵Biomed Primate Res Ctr, Rijswijk, The Netherlands
234	Cell Biology of Trim5a Xiaolu Wu*, E Campbell, and T Hope Univ of Illinois, Chicago, USA
235	Hijacking Cullin5-ElonginB/C E3 Ligase by Adenovirus E4orf6 and Lentiviral Vif through Viral-specific BC Boxes K Luo¹, Elana Ehrlich*², Z Xiao¹, Y Yu², B Liu², G Ketner², and X F Yu² ¹Zhejiang Univ, China and ²Johns Hopkins Univ, Bloomberg Sch of Publ Hlth, Baltimore, MD, USA
236	APOBEC-3C Induces Non-lethal Hypermutation in HIV-1: Implications for Viral Evolution Khaoula Bourara*¹, T Liegler¹, R Hance¹, J Kropp¹, and R Grant² ¹Gladstone Inst of Virology and Immunology, Univ of California, San Francisco, USA and ²Gladstone Inst of Virology and Immunology, Univ of California, San Francisco, USA
237	Inhibition of Human T-cell Leukemia Virus Type 1 by APOBEC3G Amane Sasada*¹, A Takaori-Kondo¹, K Shirakawa¹, M Kobayashi¹, A Abudu¹, M Hishizawa¹, K Imada¹, Y Tanaka², and T Uchiyama¹ ¹Grad Sch of Med, Kyoto Univ, Japan and ²Grad Sch and Faculty of Med, Univ of the Ryukyus, Okinawa, Japan
238	Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongins B/C Complex Akifumi Takaori-Kondo*¹, M Kobayashi¹, Y Miyauchi², K Iwai², and T Uchiyama¹ ¹Grad Sch of Med, Kyoto Univ, Japan and ²Grad Sch of Med, Osaka City Univ, Japan
239	APOBEC3B and APOBEC3C Are Potent Inhibitors of SIV but Not HIV-1 Qin Yu*¹, D Chen¹, R König¹, R Mariani¹, D Unutmaz², and N Landau¹ ¹Salk Inst for Biological Studies, San Diego, CA, USA and ²Vanderbilt Univ, Nashville, TN, USA
240	Differential APOBEC3G/3F Neutralization Activities of Vif in vivo Viviana Simon*, V Zennou, D Murray, Y Huang, D Ho, and P Bieniasz Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY, USA
241	Several Human APOBEC3 Proteins Are Potent Cellular Inhibitors of HIV-1 Brian Doehle*¹, A Schaefer², H Wiegand², and B Cullen^1,3,4 ¹Duke Univ, Durham, NC, USA; ²Howard Hughes Med Inst, Durham, NC, USA; ³Howard Hughes Med Inst, Durham, NC, USA; and ⁴Howard Hughes Med Inst
242	Analysis of HIV-1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation in vivo Simon Mallal*, C Pace, D Nolan, J Keller, C Moore, F Carvalho, A Patterson, K Sutton, and S Gaudieri Ctr for Clin Immunology and Biomed Statistics, Perth, Australia
243	Expression of APOBEC3G in Human CD4⁺ Lymphocytes In Vivo MariaPia De Pasquale*, T Allos, L Sutton, T Gebretsadik, N Madison, M Vetter, and R D'Aquila Vanderbilt Univ Med Ctr, Nashville, TN, USA
244	Regulation of Apobec 3F and HIV-1 Vif by Vif-Cul5-ElonB/C E3 Ubiquitin Ligase Phuong Sarkis*¹, B Liu^1,2, K Luo^1,3, Y Yu¹, and X F Yu^1,3 ¹Johns Hopkins Univ, Bloomberg Sch of Publ Hlth, Baltimore, MD, USA; ²Harbin Veterinary Res Inst, Chinese Academy of Agricultural Sci, China; and ³Zhejiang Univ, China
245	Differential Expression of APOBEC3G in Distinct Dendritic Cell Populations Harold Oliva*¹, R Pacheco², N Climent¹, F Borras³, F Garcia¹, C Gil¹, J Martínez², J Miró⁴, R Franco², N Navaratnam⁵, J Gatell¹, and T Gallart¹ ¹Hosp Clin Inst of Invest Biomed, Univ of Barcelona, Spain ; ²Univ of Barcelona, Spain; ³Hosp Germans Trias I Pujol, Badalona, Spain; ⁴Hosp Clin Inst of Invest Biomed, Univ of Barcelona, Spain ; and ⁵Med Res Council, Hammersmith Hosp Campus, London, UK